News coverage about Endologix (NASDAQ:ELGX) has trended somewhat positive on Monday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Endologix earned a daily sentiment score of 0.22 on Accern’s scale. Accern also gave news coverage about the medical instruments supplier an impact score of 45.999531812771 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
ELGX has been the topic of several analyst reports. Canaccord Genuity restated a “hold” rating and issued a $5.00 target price on shares of Endologix in a research report on Wednesday, September 27th. Royal Bank of Canada reiterated a “hold” rating and set a $5.00 price target on shares of Endologix in a research report on Tuesday, October 3rd. Stifel Nicolaus set a $6.00 price target on Endologix and gave the company a “hold” rating in a research report on Friday, October 6th. Piper Jaffray Companies reissued an “overweight” rating on shares of Endologix in a research note on Tuesday, December 12th. Finally, BidaskClub lowered Endologix from a “buy” rating to a “hold” rating in a research note on Friday, December 15th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. Endologix presently has a consensus rating of “Hold” and an average price target of $5.41.
Endologix (NASDAQ ELGX) opened at $4.59 on Monday. Endologix has a 1-year low of $4.08 and a 1-year high of $7.66. The company has a current ratio of 2.90, a quick ratio of 2.11 and a debt-to-equity ratio of 2.61. The firm has a market capitalization of $383.05, a PE ratio of -4.94 and a beta of 0.72.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.